C-MET enhances chemoresistance of human ovarian cancer cells [100], while the CDKN2A (p16) gene is a candidate for the tumor-suppressor gene [101], N-cadherin protein increases cell metastatic capacity [102], and finally P-glycoprotein/ABCB1 encodes drug transporter systems and activates multi-drug resistance [103]. Here, CDKN2A is linked to ovarian carcinoma.